<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109430">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02120664</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-A22</org_study_id>
    <nct_id>NCT02120664</nct_id>
  </id_info>
  <brief_title>Florbetapir Calibration to the Centiloid Scale</brief_title>
  <official_title>A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission
      Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Florbetapir SUVr Conversion to Centiloid Units</measure>
    <time_frame>up to 70 minutes post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Conversion of florbetapir (18F) PET SUVr to Centiloid units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of florbetapir (18F) centiloid and 11C-PiB centiloid</measure>
    <time_frame>up to 70 minutes post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Spearman rank correlation analysis between 11C-PiB and florbetapir (18F) SUVr as converted to centiloid units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of PET Images in Control Subjects.</measure>
    <time_frame>up to 70 minutes post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Variance and coefficient of variation for 11C-PiB and florbetapir (18F) SUVr.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Amyloid Negative Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F)  and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amyloid Positive Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F)  and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florbetapir (18F)</intervention_name>
    <arm_group_label>Amyloid Negative Subjects</arm_group_label>
    <arm_group_label>Amyloid Positive Subjects</arm_group_label>
    <other_name>Florbetapir F 18</other_name>
    <other_name>Amyvid</other_name>
    <other_name>18F-AV-45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-PiB</intervention_name>
    <arm_group_label>Amyloid Negative Subjects</arm_group_label>
    <arm_group_label>Amyloid Positive Subjects</arm_group_label>
    <other_name>Pittsburgh Compound B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cognitively Normal Subjects

               -  Males or females ≥ 21 and ≤ 45 years of age

               -  Mini-mental state examination (MMSE) ≥ 29

          -  Clinically Diagnosed AD Subject

               -  Males or females ≥ 50 years of age

               -  Meet clinical criteria for dementia due to probable AD

               -  MMSE ≥ 16 and ≤ 26

          -  Possible AD Subject

               -  Males or females ≥ 50 years of age

               -  Meet clinical criteria for dementia due to possible AD

               -  MMSE ≥ 16 and ≤ 26

          -  MCI Subject

               -  Males or females ≥ 60 years of age with cognitive impairment (not dementia)

               -  MMSE &gt;24 and &lt;29

          -  At Risk Elderly Subject

               -  Cognitively normal males or females that are known ApoE4 carriers and ≥ 75 years
                  of age

               -  MMSE ≥ 27

        Exclusion Criteria:

          -  Have had or currently have a diagnosis of neurodegenerative disorders other than AD

          -  Have a current serious or unstable illness that could interfere with completion of
             the study

          -  Subject has a known brain lesion, pathology or traumatic brain injury

          -  Have received or participated in a trial with investigational medications in the past
             30 days

          -  Have had a radiopharmaceutical imaging or treatment procedure within 7 days of  study
             imaging session

          -  Females of childbearing potential who are not surgically sterile, not refraining from
             sexual activity or not using reliable methods of contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avid Clinical Operations</last_name>
    <phone>215-298-0700</phone>
    <email>clinicaloperations@avidrp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
